Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Profit After Tax (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Profit After Tax readings, the most recent being -$4.8 million for Q4 2025.

  • On a quarterly basis, Profit After Tax fell 141.16% to -$4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$9.7 million, a 2134.4% decrease, with the full-year FY2025 number at -$9.7 million, down 2134.17% from a year prior.
  • Profit After Tax hit -$4.8 million in Q4 2025 for Fennec Pharmaceuticals, down from -$638000.0 in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $12.8 million in Q1 2024 to a low of -$8.0 million in Q3 2022.
  • Median Profit After Tax over the past 5 years was -$4.2 million (2021), compared with a mean of -$3.3 million.
  • The widest YoY moves for Profit After Tax: up 312.11% in 2024, down 207.18% in 2024.
  • Fennec Pharmaceuticals' Profit After Tax stood at -$4.2 million in 2021, then crashed by 63.58% to -$6.9 million in 2022, then surged by 61.1% to -$2.7 million in 2023, then grew by 25.99% to -$2.0 million in 2024, then plummeted by 141.16% to -$4.8 million in 2025.
  • The last three reported values for Profit After Tax were -$4.8 million (Q4 2025), -$638000.0 (Q3 2025), and -$3.2 million (Q2 2025) per Business Quant data.